Abstract

The present invention relates to the use of 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro- 1 H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone (Formula (I)) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of dementia and/or a neurodegenerative disease (e.g. Alzheimer's disease, in particular cognitive impairment therein), schizophrenia (e.g. cognitive impairment associated therewith), attention deficit hyperactivity disorder, somnolence, or epilepsy, in a human, by oral administration to the human using an escalating dosage regimen comprising: - an initial dosage regimen of from 2 to 15 micrograms (preferably from 5 to 10 micrograms) of the 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7- yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day, and subsequently - a maintenance dosage regimen of from 30 to 150 micrograms (preferably from from 40 to 80 micrograms) of the 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3- benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day.


Claims

Sign in to the Lens

Release 5.10.0: Improved patent search performance, saved query alerts, increased user privacy and more!

Improved Search Performance

Upgraded patent search index servers to improve search performance.

Saved Query Alerts.

Improvements to in saved query alerts emails and better formatting of links.

Increased User Privacy.

Removed Google Maps dependency in a Patents Family page.